Skip to content
AnalystLens

Exelixis Quarterly Report for Q3 Ended Oct 2, 2026

Filing Date
Filed October 29, 2026
Period End
October 2, 2026
Security
EXEL
One revenue dollarkept$0.33
In the record · 2016–202610-K1110-Q358-K119

EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’17Jan ’17
  2. Material agreement8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Nov ’25Nov ’25

Summary

Summary of the 10-Q filed October 29, 2026. Cited figures are marked; the original filing is the authoritative source.

Exelixis, Inc. reported net product revenues of $604.9 milliona for the third quarter of 2026, up from $542.9 million a year earlier, and total revenues of $658.7 million versus $597.8 million.

Net income was $218.1 millionb, or $0.85 per diluted share, compared with $193.6 million, or $0.69 per diluted share, in the prior-year quarter. Growth was driven mainly by CABOMETYX, with the company citing a 6% increase in units sold and a 5% increase in average net selling price, while research and development ($209.5 million) and selling, general and administrative ($154.6 million) expenses rose as the company prepared for zanzalintinib's anticipated launch. The company ended the period with $1.4 billion in cash, cash equivalents and marketable securities, down from $1.7 billion at December 31, 2025, largely due to $1.0 billion of share repurchases in the first nine months.

Operating cash flow was $839.5 millionc for the nine months, and management states it expects current resources to fund operations for at least 12 months. Under the May 2026 repurchase program, $347.9 million remained available as of September 30, 2026.

Key pipeline and legal developments include the FDA extending the review of the zanzalintinib NDA (with atezolizumab for metastatic colorectal cancer) to a PDUFA date of March 3, 2027, and the Federal Circuit affirming the validity of several CABOMETYX patents against MSN, with a separate trial scheduled for November 2026. The FDA also granted full approval to Handa's 505(b)(2) NDA for a cabozantinib product on September 3, 2026, and the company entered a settlement and license agreement with Azurity on October 28, 2026.

Key Highlights

  1. Total revenues of $658.7 million for Q3 2026, up from $597.8 million in Q3 2025; nine-month total revenues of $1.90 billion versus $1.72 billion.
  2. Net product revenues of $604.9 million for Q3 2026, with CABOMETYX at $603.2 million; the company attributed growth to a 6% increase in CABOMETYX units sold and a 5% higher average net selling price.
  3. Net income of $218.1 million ($0.85 diluted EPS) for Q3 2026 versus $193.6 million ($0.69 diluted EPS) a year earlier.
  4. Cash, cash equivalents and marketable securities totaled $1.4 billion at September 30, 2026, down from $1.7 billion at December 31, 2025, mainly reflecting $1.0 billion of nine-month share repurchases.
  5. Zanzalintinib NDA with atezolizumab for previously treated metastatic colorectal cancer had its PDUFA target action date extended to March 3, 2027 after a major amendment.
  6. Federal Circuit affirmed validity of the '439, '440 and '015 patents against MSN; the effective date of any MSN generic approval shall not be earlier than January 15, 2030, subject to further proceedings.
  7. FDA granted full approval to Handa's 505(b)(2) NDA for a cabozantinib product on September 3, 2026, and the company is evaluating legal and strategic options.

Follow one dollar

Of each $1.00 of revenue in Q3 FY2027, Exelixis kept $0.33.

  1. Revenue$658.7M100.0%
  2. Cost of revenue−$26.2M4.0%
  3. Gross profit$632.5M96.0%
  4. Operating costs−$364.0M55.3%
  5. Operating income$268.4M40.8%
  6. Interest, other & tax−$50.3M7.6%
  7. Net income$218.1M33.1%
Computed from 10-QQ3 FY2027filed October 29, 2026Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q3 FY2027 against Q3 FY2026

Line itemQ3 FY2027Q3 FY2026Change
Revenue$658.70M$597.75M+10.2%
Cost of Revenue$26.23M$18.57M+41.2%
Gross Profit$632.46M$579.18M+9.2%
R&D Expenses$209.48M$199.16M+5.2%
SG&A Expenses$154.56M$123.66M+25.0%
Operating Expenses$390.27M$361.21M+8.0%
Operating Income$268.42M$236.54M+13.5%
Net Income$218.09M$193.58M+12.7%
EPS (Basic)$0.88$0.72+22.2%
EPS (Diluted)$0.85$0.69+23.2%
Shares Outstanding (Basic)246.76M268.42M−8.1%
Shares Outstanding (Diluted)255.75M278.54M−8.2%

Frequently Asked Questions

  1. What drove the increase in revenue this quarter?

    Net product revenues rose 11% to $604.9 million, primarily due to a 6% increase in CABOMETYX units sold, reflecting demand for CABOMETYX with nivolumab in first-line advanced RCC and for previously treated NET, plus a 5% increase in average net selling price. Collaboration revenues were roughly flat at $53.8 million.

  2. How are generic and follow-on competitors affecting CABOMETYX?

    The company disclosed ANDA and 505(b)(2) NDA filings from MSN, Teva, Cipla, Biocon, Sun, Accord, Azurity, Almatica and Handa. The FDA approved Handa's 505(b)(2) NDA on September 3, 2026. The company states that any launch of these follow-on products could significantly decrease U.S. CABOMETYX revenues. The Azurity settlement allows a license beginning December 1, 2030, and the generic effective date for settled products remains January 1, 2031.

  3. What is the status of zanzalintinib's regulatory review?

    The FDA accepted the NDA for zanzalintinib with atezolizumab for previously treated metastatic colorectal cancer under a standard review. In September 2026 the FDA extended the review by three months after a major amendment, and the updated PDUFA target action date is March 3, 2027.

  4. How much capital did the company return to shareholders, and what remains available?

    The company recorded $1.0 billion in payments for common stock repurchases in the nine months ended September 30, 2026. Under the May 2026 program, it repurchased 7.4 million shares for $402.1 million, and approximately $347.9 million remained available through December 31, 2027.

  5. Does the company expect its cash to fund operations?

    Management anticipates that current cash, cash equivalents and marketable securities, together with net product and collaboration revenues, will enable operations for at least 12 months and for the foreseeable future thereafter. Net cash provided by operating activities was $839.5 million for the nine months ended September 30, 2026.